A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers

Advanced biliary tract cancers (ABTC) are among the deadliest malignancies with limited treatment options after progression on standard-of-care chemotherapy, which includes gemcitabine (GEM) and oxaliplatin (OX). The epidermal growth factor receptor inhibitor erlotinib has been explored in ABTC with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Goff, Laura W., Cardin, Dana B., Whisenant, Jennifer G., Du, Liping, Koyama, Tatsuki, Dahlman, Kimberly B., Salaria, Safia N., Young, Ruth T., Ciombor, Kristen K., Gilbert, Jill, Smith, Stephen James, Chan, Emily, Berlin, Jordan
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2016
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5306261/
https://ncbi.nlm.nih.gov/pubmed/27853997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0406-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados